mRNA melanoma vaccine trial demonstrates efficacy in preventing cancer recurrence

A large-scale clinical trial indicates that mRNA-based vaccine technology successfully trained the immune system to prevent melanoma recurrence. While this marks a significant milestone in oncology, the long-term durability of the immune response and scalability across different cancer types remain to be established.